OSLO, Norway--(BUSINESS WIRE)--Affitech AS, the Norwegian human antibody therapeutics company, announced today its membership in the newly inaugurated Norwegian Center for Stem Cell Based Tumor Therapy (CAST). In the frame of this participation, Affitech will use its proprietary CBAS™ (Cell Based Antibody Selection) platform to identify molecules of clinical interest. CBAS™ is a reverse screening approach which utilizes both patient-derived and naïve antibody libraries to rapidly generate fully human antibodies and their cognate antigens when present in their natural setup.
